An interventional study of Pilates in Multiple Sclerosis, Pilates Exercise and Walking, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Multiple Sclerosis by University of Illinois at Chicago — 6 open to participants now, 9 under way, none of them phase 3. Multiple Sclerosis · University of Illinois at Chicago.
Among the 15 studies in Multiple Sclerosis by University of Illinois at Chicago, this one is the 10th largest by planned enrollment, is one of 3 that started in 2025, is one of 14 with no phase, and was the 13th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →6 of the 15 studies in Multiple Sclerosis by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:
University of Illinois at Chicago · Sites in United States
Ages 40–90
University of Illinois at Chicago · Sites in United States
Ages 18–90
University of Illinois at Chicago · Sites in United States
Ages 18+
University of Illinois at Chicago · Sites in United States
Ages 18–64
University of Illinois at Chicago · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 52 across the 15 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
2 of the studies in Multiple Sclerosis by University of Illinois at Chicago that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07355387University of Illinois at ChicagoHome Based Functional Balance Intervention for Multiple Sclerosis | 2026-11-24 |
| NCT06341023University of Illinois at ChicagoFunctional Balance Intervention in Multiple Sclerosis | 2027-01-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Multiple Sclerosis by University of Illinois at Chicago, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.
Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.
Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.
The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Pilates group
Behavioral: Pilates
Waitlist Group
REMOTLY PILATES EXERCISE
Change from baseline in walking endurance (Six-Minute Walk Test distance)
Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in walking speed (Timed 25-Foot Walk)
Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in balance (Berg Balance Scale)
Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in fatigue (Fatigue Severity Scale)
Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in pain (Short-form McGill Pain Questionnaire)
Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)
Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in verbal learning and memory (California Verbal Learning Test-II)
Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)
Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in depression symptoms
Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in anxiety symptoms
Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using.
Time frame: Baseline and 16 weeks (end of treatment)
Change from baseline in health-related quality of life
Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure.
Time frame: Baseline and 16 weeks (end of treatment)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 25 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Jun 2026 → Nov 2025 and primary completion Nov 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →